Interview with Harry Flore, CEO, HAL Allergy Group
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
Address: Wilgenlaan 5 • 1161 JK Zwanenburg,Netherlands
Tel: 31 (0) 20 / 407 20 72
Web: http://www.daiichi-sankyo.nl/
DAIICHI SANKYO’s goal is to establish itself as a ‘Global Pharma Innovator.’ The pharmaceutical industry is one of the 21st century’s growth industries, and what this vision of the company signifies is DAIICHI SANKYO making it the leading industry of Japan, a nation built on the platform of scientific and technological creativity, and establishing itself as a firm presence by continued success as a flagship company. This is the vision that guides the development of our global pharmaceutical operations.
DAIICHI SANKYO’s products are used not only in Japan but also in many parts of the world including Asia, Europe and the United States. To pick up on global needs all over the world and have these reflected in global pharmaceutical operations, we are active in promoting information exchange in a number of areas including research and development, supply chain management and marketing.
We are determined to contribute to the health of people everywhere by creating new medicines in popular use throughout the world, and delivering them to places where medical treatment is required, transcending national borders.
We have about 2,300 overseas medical representatives in 33 locations, mainly in Europe and the United States. From this point on, we are aiming for growth through our own development and sales, mainly in the United States, and to this end, we are planning to expand our overseas development and sales bases. While making efforts to develop innovative new medicines, we have become established as a firm presence in the global market for pharmaceutical products by implementing the highest standard of operational efficiency in the industry in order to ‘respond to the medical needs of people everywhere.’
Our U.S. subsidiary, Daiichi Sankyo, Inc. (DSI) has research and development and sales sections, and as the organization that forms the nucleus of our U.S. operations, is expected to grow in the future.
Our European subsidiary, Daiichi Sankyo Europe GmbH (DSE), is headquartered in Munich, Germany, and has around 800 medical representatives in operational bases in 10 European countries.
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
You are still relatively new to the Netherlands having been here for one year. This must be a very insightful experience abroad. What were your initial expectations and first impressions…
You began as managing director of this Dutch affiliate close to one year ago. What was the trajectory that led you to this position and what were your initial impressions…
Since its founding Galapagos has operated with a hybrid business model which has combined its internal discoveries with service activities. This model has worked quite well as it has now…
As much as this report is about business trends and insights, we also like to portray the personalities of the industry in the markets that we cover. What has been…
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Promega is a truly global company with a vast international presence. What would you say is the strategic importance that the Benelux affiliate has assumed within Promega’s global network? Promega…
See our Cookie Privacy Policy Here
